Perioperative Rosuvastatin Fails to Curb Cardiac Surgery ComplicationsPerioperative Rosuvastatin Fails to Curb Cardiac Surgery Complications
Although the adverse effects on renal function may relate to patient ethnicity or rosuvastatin use, "a class effect of statin therapy in patients undergoing cardiac surgery cannot be ruled out," the authors said. Heartwire from Medscape
A new study aims to elucidate the link between PCSK9 inhibitors and glucose metabolism. Might they increase the risk of diabetes, as statins have been shown to do?European Heart Journal
Knowing the odds of side effects and making sure to get periodic checkups that would pick up an adverse reaction, I chose to focus on the drugs ’ potential benefits.
Authors: Cook MJ, Sorial AK, Lunt M, Board TN, O'Neill TW Abstract OBJECTIVE: To determine whether the timing and also duration of statin exposure following total hip/knee arthroplasty (THA/TKA) influences the risk of revision arthroplasty. METHODS: Subjects from the Clinical Practice Research Datalink, a large population-based clinical database, who had THA/TKA from 1988-2016 were included. Propensity score adjusted Cox regression models were used to determine the association between statin exposure and the risk of revision THA/TKA, i) at any time and ii) if first exposed 0-1, 1-5, or>5 years following THA/...
SATURDAY, March 16, 2019 -- People who've already had a heart attack or stroke can cut their odds for another one in half if they regularly take cholesterol-lowering statins. Yet new research found that only about 6 percent of patients take these...
CONCLUSION: Measurement of serum anti-apo B-100 autoantibodies can be useful for the evaluation of CVD risk in patients with diabetes receiving statin treatment. PMID: 30867375 [PubMed - as supplied by publisher]
Coronary artery disease is a leading cause of morbidity and mortality after heart transplantation (HT), resulting from cardiovascular risk factors and those associated with a proinflammatory state. Statins reduce incidence of post-HT cardiac allograft vasculopathy (CAV); it is unknown whether they act through their lipid-lowering effects or through alternative mechanisms.
In this study, we analyzed myocardial gene expression profiles in cardiac allografts after donor simvastatin treatment.
Hyperlipidemia is a major factor in the development of graft vasculopathy (GVP) after heart transplant. The incidence of hyperlipidaemia in heart transplant (HTX) patients under immunosuppressive therapy is 74% in the first year, and 91% in the first five years. Lipid-lowering therapy with statins presents a great challenge due to interactions and adverse effects. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have already proven very effective in high-risk cardiovascular patients.
Primary graft dysfunction (PGD) is the main cause of mortality during the first month and the second one within the first year after lung transplantation (LT). Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, have been proposed as an effective class of drugs to reduce serum cholesterol levels due to their immunomodulatory and anti-inflammatory effects unrelated to their cholesterol-lowering function. We hypothesized that preoperative statin therapy is associated with decreased incidence of PGD after LT.
Statin therapy offers long-term morbidity and mortality benefits after orthotopic heart transplant (OHT), regardless of lipid levels. Multiple statins have been specifically studied in post-OHT patients, showing decrease in dyslipidemia and development of cardiac allograft vasculopathy (CAV). CAV is an accelerated form of coronary artery disease characterized by concentric fibrous intimal hyperplasia along the length of coronary vessels. CAV is detectable by angiography in 43% of survivors in the first 8 years after OHT.